Money

Found 78,486 articles

• 

  Latest Data for Karuna’s Schizophrenia Drug Spark Investor Concern

  3/24/2023

  Analysts point to a missed secondary endpoint and cardiovascular risks that may delay FDA approval as possible reasons for the unexpected drop in Karuna's stock following the data reveal.

• Allarity Therapeutics Announces Reverse Stock Split of Common Stock

  3/24/2023

  Allarity Therapeutics, Inc. announced that it intends to effect a reverse stock split of its common stock, at a ratio of 1 post split share for every 35 pre-split shares.

• Ryvu Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

  3/24/2023

  Ryvu Therapeutics reported financial results for the fourth quarter and the full year ended December 31, 2022, and provided a corporate update.

• Evotec Receives US$ 6.6 m Grant for Drug Discovery in Tuberculosis

  3/24/2023

  Evotec SE announced that the Company has received a US$ 6.6 m grant from The Bill & Melinda Gates Foundation for drug discovery in tuberculosis.

• Brii Biosciences Provides Corporate Update and Reports Full-Year 2022 Financial Results

  3/24/2023

  Brii Biosciences Limited, a biotechnology company developing therapies to improve patient health and choice across diseases with high unmet needs, announced a corporate update and reported its annual results for the year ended December 31, 2022.

• Resilience Approved for $410M Financing from the Department of Defense, in Partnership with the Development Finance Corporation, to Establish Resilient Biomanufacturing Capacity

  3/24/2023

  National Resilience, Inc. (Resilience) today announced that it has signed a finance agreement for $410 million in long-term loan financing from the U.S. Department of Defense (DoD), working with the U.S. International Development Finance Corporation (DFC).

• Sparta Science Raises a New Round of Funding to Help Organizations Optimize Movement Health Outcomes at Scale

  3/23/2023

  Sparta Science announced an additional round of funding led by Spring Lake Equity Partners.

• Sirona Biochem Announces Debenture Financing

  3/23/2023

  Sirona Biochem Corp. is pleased to announce a non-brokered private placement offering of unsecured, convertible debentures.

• Genelux Corporation to Ring Nasdaq Opening Bell on March 29, 2023

  3/23/2023

  Genelux Corporation announced that it will ring the Nasdaq Stock Market opening bell on Wednesday, March 29, 2023 to commemorate its initial public offering, which occurred in January.

• Arch Biopartners Receives Funding for Development of LSALT Peptide Drug Program

  3/23/2023

  Today, Arch Biopartners Inc. announced that Arch is receiving advisory services and up to $4,000,000 in funding from the National Research Council of Canada Industrial Research Assistance Program (“NRC IRAP”) to support the research and development of the LSALT peptide (Metablok) program.

• Nyxoah Announces a $15 Million Private Placement Financing

  3/23/2023

  Nyxoah SA announced a €13.35 million private placement financing from the sale of 2,047,544 new ordinary shares at a price per share of €6.52, the closing price on Euronext Brussels on March 23, 2023.

• LUNGevity Announces Pierre Massion Young Investigator Awards for Early Detection Research

  3/23/2023

  LUNGevity Foundation is honored to announce the recipients of the Pierre Massion Young Investigator Award for Lung Cancer Early Detection Research.

• Aptose Reports Results for the Fourth Quarter and Full Year 2022

  3/23/2023

  Aptose Biosciences Inc. announced financial results for the fourth quarter and year ended December 31, 2022, and provided a corporate update.

• IntelGenx to Report Fourth Quarter and Full Year 2022 Financial Results on March 30, 2023 – Conference Call to Follow

  3/23/2023

  IntelGenx Technologies Corp., a leader in pharmaceutical films, announced that it will release its fourth quarter and full year 2022 financial results after market close on Thursday, March 30, 2023.

• Harrow Announces Fourth Quarter and Year-End 2022 Financial Results

  3/23/2023

  Harrow, a leading U.S. eyecare pharmaceutical company, announced results for the fourth quarter and year ended December 31, 2022.

• Medtronic Announces Pricing of $2.0 Billion of Senior Notes

  3/23/2023

  Medtronic plc announced that its wholly-owned subsidiary, Medtronic Global Holdings S.C.A., has priced an offering of $1,000,000,000 principal amount of 4.25% senior notes due 2028 and $1,000,000,000 principal amount of 4.50% senior notes due 2033.

• Nordic Nanovector - Annual and Remuneration Reports Approved

  3/23/2023

  On 22 March 2023, the Board of Directors of Nordic Nanovector ASA approved the Company's financial statements for 2022.

• PureTech Health and Royalty Pharma Enter into KarXT Royalty Agreement for up to $500 Million

  3/23/2023

  PureTech Health plc and Royalty Pharma announced that Royalty Pharma has acquired an interest in PureTech’s royalty in Karuna Therapeutics’ KarXT for up to $500 million, with $100 million in cash up front and up to $400 million in additional payments contingent on the achievement of certain regulatory and commercial milestones.

• NovaBay Pharmaceuticals to Hold 2022 Fourth Quarter and Full Year Conference Call on March 30, 2023

  3/23/2023

  NovaBay® Pharmaceuticals, Inc. announces that it will report financial results for the three and 12 months ended December 31, 2022 after market close on Thursday, March 30, 2023 and will hold an investment community conference call that day beginning at 4:30 p.m. Eastern time.

• Poxel Reports Financial Results for Full Year 2022 and Provides Corporate Update

  3/23/2023

  POXEL SA, a clinical stage biopharmaceutical company developing innovative treatments for serious chronic diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis and rare metabolic disorders, announced its results for the year ended December 31, 2022 and provided a corporate update.